基本信息
浏览量:296
职业迁徙
个人简介
My laboratory is involved in translational research activities in genitourinary malignancies, especially renal cell carcinoma (RCC), which is the most common form of kidney cancer. Our research efforts in this area have focused on the identification of novel oncogenes and tumor suppressor genes that could function as new drug targets and thus might lead to new therapeutic approaches for patients with RCC. We conducted the first genome-wide analysis of copy-number changes and gene expression profiles in both sporadic and Von-Hippel Lindau (VHL) disease-associated clear cell renal cell carcinomas (ccRCC) (Beroukhim et al, Cancer Res 2009). Results showed that sporadic tumors without biallelic VHL inactivation are heterogeneous and include tumors with genomic profiles highly dissimilar to the majority of ccRCC, suggesting that they represent a separate group of cancers that do not respond to treatments that target the VHL pathway. We subsequently continued to work on the molecular characterization ccRCC as part of the NCI-sponsored The Cancer Genome Atlas (TCGA) effort(Creighton et al, Nature 2013).
In the past decade, the availability of approved agents with distinct mechanisms of action (immunotherapy, vascular endothelial growth factor [VEGF] pathway, and mammalian target of rapamycin [mTOR] inhibitors) has complicated treatment decisions for patients with advanced RCC. For this reason, my group has been very interested in building predictive models (for either FDA-approved or investigational drugs) that can help medical oncologists select the most appropriate therapy for a given patient. Over the past years, we have extensively analyzed the role of the enzyme carbonic anhydrase IX (CAIX) and other elements of the VHL-HIF pathway both as diagnostic and predictive biomarkers for VEGF-targeted therapy in ccRCC. More recently, we performed a multi-institutional study, which demonstrated that mutations in MTOR pathway genes are associated with response to mTOR inhibitors in patients with metastatic RCC, providing a potential predictive biomarker for rapalogs in this tumor type (Kwiatkowski et al, Clin Cancer Res 2016). In the past few years, my laboratory has also been deeply involved in the characterization of the expression of immunomodulatory molecules, including PD-L1, in tumors form patients with RCC and bladder cancer. This work has provided important insights into the role of PD-L1 as a potential predictive biomarker and a target of immunotherapy in genitourinary cancers. For instance, our analysis of PD-L1 expression in non-clear-cell Renal Cell Carcinoma (non-ccRCC) tissue samples provided a rationale for conducting clinical trial testing the efficacy of PD-1 inhibitors in patients with metastatic non-ccRCC (Choueiri et al, Ann Oncol 2014). Moreover, our detailed comparison of PD-L1 expression in primary ccRCCs and corresponding metastases highlighted the heterogeneity of PD-L1 expression in this tumor type, implying that accurate assessment of PD-L1 as a predictive biomarker for PD-1 blockade in ccRCC may require analysis of metastatic lesions (Callea et al, Cancer Immunol Res 2015). Our current efforts in this field of research are directed at identifying biomarkers of response to PD-1/PD-L1 immune checkpoints blockade through the analysis of clinical trial patient cohorts.
In the past decade, the availability of approved agents with distinct mechanisms of action (immunotherapy, vascular endothelial growth factor [VEGF] pathway, and mammalian target of rapamycin [mTOR] inhibitors) has complicated treatment decisions for patients with advanced RCC. For this reason, my group has been very interested in building predictive models (for either FDA-approved or investigational drugs) that can help medical oncologists select the most appropriate therapy for a given patient. Over the past years, we have extensively analyzed the role of the enzyme carbonic anhydrase IX (CAIX) and other elements of the VHL-HIF pathway both as diagnostic and predictive biomarkers for VEGF-targeted therapy in ccRCC. More recently, we performed a multi-institutional study, which demonstrated that mutations in MTOR pathway genes are associated with response to mTOR inhibitors in patients with metastatic RCC, providing a potential predictive biomarker for rapalogs in this tumor type (Kwiatkowski et al, Clin Cancer Res 2016). In the past few years, my laboratory has also been deeply involved in the characterization of the expression of immunomodulatory molecules, including PD-L1, in tumors form patients with RCC and bladder cancer. This work has provided important insights into the role of PD-L1 as a potential predictive biomarker and a target of immunotherapy in genitourinary cancers. For instance, our analysis of PD-L1 expression in non-clear-cell Renal Cell Carcinoma (non-ccRCC) tissue samples provided a rationale for conducting clinical trial testing the efficacy of PD-1 inhibitors in patients with metastatic non-ccRCC (Choueiri et al, Ann Oncol 2014). Moreover, our detailed comparison of PD-L1 expression in primary ccRCCs and corresponding metastases highlighted the heterogeneity of PD-L1 expression in this tumor type, implying that accurate assessment of PD-L1 as a predictive biomarker for PD-1 blockade in ccRCC may require analysis of metastatic lesions (Callea et al, Cancer Immunol Res 2015). Our current efforts in this field of research are directed at identifying biomarkers of response to PD-1/PD-L1 immune checkpoints blockade through the analysis of clinical trial patient cohorts.
研究兴趣
论文共 9 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Shidong Jia,Xueliang Gao, Sang Hyun Lee, Sauveur-Michel Maira, Xiaoqiu Wu,Edward C. Stack,Sabina Signoretti,Massimo Loda,Jean J. Zhao,Thomas M. Roberts
crossref(2023)
Molecular Therapy - Oncolytics (2021)
Melanie M. Frigault,Daniel Stetson,Elizabeth M. Maloney, Joseph F. Kramkowski,Evan Barry, E.K. Lamberth,Sabina Signoretti,Celina M. D’Cruz,Brian Dougherty,J. Carl Barrett,Toni K. Choueiri
Annals of Oncology (2016): vi535-vi535
Roman K. Thomas,Alissa C. Baker, Ralph M. Debiasi,Wendy Winckler,Thomas Laframboise,William M. Lin,Meng Wang, Whei Feng,Thomas Zander,Laura E. MacConnaill, Jeffrey C. Lee, Rick Nicoletti,
user-5f8cf9244c775ec6fa691c99(2007)
引用3浏览0引用
3
0
Nabeel Bardeesy,Jeffrey Morgan,Manisha Sinha,Sabina Signoretti, Shefali Srivastava,Massimo Loda,Glenn Merlino,Ronald A. DePinho
Molecular and Cellular Biologyno. 2 (2002): 635-643
Manisha Sinha, Aram F. Hezel,Sabina Signoretti, Nathaniel A. Hathaway, Norman E. Sharpless,Massimo Loda,Daniel R. Carrasco, Ronald A. DePinho
semanticscholar
引用71浏览0引用
71
0
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn